Tissue, I hardly know you!: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==20.20 Tissue Engineering Group== | |||
*Group members: Anna, Amber, Derek, Prarthna, Mike, Robbie, and Aditya | *Group members: Anna, Amber, Derek, Prarthna, Mike, Robbie, and Aditya | ||
Line 28: | Line 28: | ||
== Perisotin Gene Sequence == | == Perisotin Gene Sequence == | ||
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=5453833 | http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=5453833 | ||
cytogenic coordinates 13q13.3] | cytogenic coordinates 13q13.3] | ||
Line 52: | Line 52: | ||
''' | ''' | ||
== | == POWERPOINT FOR TECH SPEC REVIEW''' == | ||
POWERPOINT FOR TECH SPEC REVIEW''' == | |||
[http://openwetware.org/wiki/Image:Targeting_and_binding_research.doc] | [http://openwetware.org/wiki/Image:Targeting_and_binding_research.doc] | ||
Line 71: | Line 70: | ||
- If it forms slowly relative to the speed at which periostin regenerates heart tissue, it is not necessary to include scar repressors. | - If it forms slowly relative to the speed at which periostin regenerates heart tissue, it is not necessary to include scar repressors. | ||
== | |||
== Competition/ Other research being done == | |||
Lepilina A, Coon AN, Kikuchi K, Holdway JE, Roberts RW, Burns CG, et | Lepilina A, Coon AN, Kikuchi K, Holdway JE, Roberts RW, Burns CG, et | ||
al. A dynamic epicardial injury response supports progenitor cell activity | al. A dynamic epicardial injury response supports progenitor cell activity | ||
Line 86: | Line 84: | ||
PRELIMINARY 6 MONTH PLAN | == PRELIMINARY 6 MONTH PLAN == | ||
[http://openwetware.org/wiki/Image:Final_Presentation-Technical_Documentation.doc] | [http://openwetware.org/wiki/Image:Final_Presentation-Technical_Documentation.doc] | ||
TECHNICAL DOCUMENTATION, ROUGH DRAFT | == TECHNICAL DOCUMENTATION, ROUGH DRAFT == | ||
[[Image:Final Presentation-Technical Documentation.doc|thumb|Description]] | [[Image:Final Presentation-Technical Documentation.doc|thumb|Description]] | ||
PARTS | == PARTS == | ||
BBa_I728950 - Periostin Sequence | BBa_I728950 - Periostin Sequence | ||
Revision as of 09:55, 29 April 2008
20.20 Tissue Engineering Group
- Group members: Anna, Amber, Derek, Prarthna, Mike, Robbie, and Aditya
Use this space to communicate with each othhttp://openwetware.org/skins/common/images/button_extlink.pnger and to formulate your ideas. Here's a link to the technical specification review requirements([1]).
PLAN OF TASKS:
--periostin part on registry /n --research safety and security /n --bactoblood /n --antibodies on heart/n --binding/n --finalize pathways from binding to NAND gates/n --6 month plan /n --competition/n --costs (as part of 6 month plan)/n --finalize collagenase part
Devices:
- targeting mechanism (specific for heart scar tissue)
- propulsion device (might not be necessary if we just let the cells travel with blood flow)
- binding device
- scar-digesting device
- healthy heart cell regeneration device
- cell death / exit device
Perisotin Gene Sequence
http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?db=nuccore&id=5453833 cytogenic coordinates 13q13.3]
[useful articles that discuss proteins expressed in cardiac scar and healthy tissue and how the two tissues differ.]
[3]
[Periostin and Myocardial Repair, Regeneration, and Recovery [4]]
[Document of gene sequence of periostin device]
http://openwetware.org/wiki/Image:Periostin_DNA_sequence.doc
[Summary of research on targeting scar heart tissue as well as binding to healthy and scarred cardiac cells.
Also includes a summary of monoclonal antibody production
and a diagram of the cardiac extracellular matrix (useful for figuring out how our bacterium will bind to it).
]
POWERPOINT FOR TECH SPEC REVIEW
TOPICS FOR ADDITIONAL RESEARCH:
1. Do we keep the bacteria in the heart until they die, or do we inject the patient with a drug to end the bacteria's life cycle.
- research the life span of the bacteria - how would the bacteria behave when they die? Do they automatically unbind from the cell or are external factors necessary.
2. Ways to prevent the immune system from responding to the bacteria
-could a coating be synthesized to prevent bacterial death and to prevent an immune system response.
3. Will Verapamil (the scar repressing agent) interact with periostin?
4. How quickly does cardiac tissue form?
- If it forms slowly relative to the speed at which periostin regenerates heart tissue, it is not necessary to include scar repressors.
Competition/ Other research being done
Lepilina A, Coon AN, Kikuchi K, Holdway JE, Roberts RW, Burns CG, et al. A dynamic epicardial injury response supports progenitor cell activity during zebrafish heart regeneration. Cell 2006;127(3):607–19.
Lien CL, Schebesta M, Makino S,Weber GJ,KeatingMT. Gene expression analysis of zebrafish heart regeneration. PLoS Biol 2006;4(8):e260.
[POWERPOINT TECH SPEC]
File:Technical Specification Review.ppt
PRELIMINARY 6 MONTH PLAN
TECHNICAL DOCUMENTATION, ROUGH DRAFT
File:Final Presentation-Technical Documentation.doc
PARTS
BBa_I728950 - Periostin Sequence
DIAGRAMS
File:C:\Users\Anna Shcherbina\Pictures\DSCF2071.jpg File:C:\Users\Derek Ju\Pictures\collagenase.jpg